scholarly journals Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism

2015 ◽  
Vol 100 (10) ◽  
pp. 3710-3717 ◽  
Author(s):  
Essi Ryödi ◽  
Saara Metso ◽  
Pia Jaatinen ◽  
Heini Huhtala ◽  
Rauni Saaristo ◽  
...  

Context: Some previous studies have suggested increased cancer risk in hyperthyroid patients treated with radioactive iodine (RAI). It is unclear whether the excess cancer risk is attributable to hyperthyroidism, its treatment, or the shared risk factors of the two diseases. Objective: The objective was to assess cancer morbidity and mortality in hyperthyroid patients treated with either RAI or surgery. Patients: We identified 4334 patients treated surgically for hyperthyroidism in Finland during 1986–2007 from the Hospital Discharge Registry and 1814 patients treated with RAI for hyperthyroidism at Tampere University Hospital. For each patient, three age- and gender-matched controls were chosen. Information on cancer diagnoses was obtained from the Cancer Registry. The follow-up began 3 months after the treatment and ended at cancer diagnosis, death, emigration, or the common closing date (December 31, 2009). Results: The overall cancer incidence was not increased among the hyperthyroid patients compared to their controls (rate ratio [RR], 1.05; 95% confidence interval [CI], 0.96–1.15). However, the risk of cancers of the respiratory tract (RR, 1.46; 95% CI, 1.05–2.02) and the stomach (RR, 1.64; 95% CI, 1.01–2.68) was increased among the patients. The overall cancer mortality did not differ between the patients and the controls (RR, 1.08; 95% CI, 0.94–1.25). The type of treatment did not affect the overall risk of cancer (hazard ratio for RAI vs thyroidectomy, 1.03; 95% CI, 0.86–1.23) or cancer mortality (hazard ratio, 1.04; 95% CI, 0.91–1.21). Conclusions: In this cohort of Finnish patients with hyperthyroidism treated with thyroidectomy or RAI, the overall risk of cancer was not increased, although an increased risk of gastric and respiratory tract cancers was seen in hyperthyroid patients. Based on this large-scale, long-term follow-up study, the increased cancer risk in hyperthyroid patients is attributable to hyperthyroidism and shared risk factors, not the treatment modality.

2019 ◽  
Vol 14 (4) ◽  
pp. 530-539 ◽  
Author(s):  
Hong Xu ◽  
Kunihiro Matsushita ◽  
Guobin Su ◽  
Marco Trevisan ◽  
Johan Ärnlöv ◽  
...  

Background and objectivesCommunity-based reports regarding eGFR and the risk of cancer are conflicting. We here explore plausible links between kidney function and cancer incidence in a large Scandinavian population–based cohort.Design, setting, participants, & measurementsIn the Stockholm Creatinine Measurements project, we quantified the associations of baseline eGFR with the incidence of cancer among 719,033 Swedes ages ≥40 years old with no prior history of cancer. Study outcomes were any type and site-specific cancer incidence rates on the basis of International Classification of Diseases-10 codes over a median follow-up of 5 years. To explore the possibility of detection bias and reverse causation, we divided the follow-up time into different time periods (≤12 and >12 months) and estimated risks for each of these intervals.ResultsIn total, 64,319 cases of cancer (affecting 9% of participants) were detected throughout 3,338,226 person-years. The relationship between eGFR and cancer incidence was U shaped. Compared with eGFR of 90–104 ml/min, lower eGFR strata associated with higher cancer risk (adjusted hazard ratio, 1.08; 95% confidence interval, 1.05 to 1.11 for eGFR=30–59 ml/min and adjusted hazard ratio, 1.24; 95% confidence interval, 1.15 to 1.35 for eGFR<30 ml/min). Lower eGFR strata were significantly associated with higher risk of skin, urogenital, prostate, and hematologic cancers. Any cancer risk as well as skin (nonmelanoma) and urogenital cancer risks were significantly elevated throughout follow-up time, but they were higher in the first 12 months postregistration. Associations with hematologic and prostate cancers abrogated after the first 12 months of observation, suggesting the presence of detection bias and/or reverse causation.ConclusionsThere is a modestly higher cancer risk in individuals with mild to severe CKD driven primarily by skin and urogenital cancers, and this is only partially explained by bias.


Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 177-177
Author(s):  
Diego Adrianzen Herrera ◽  
Insu Koh ◽  
Radhika Gangaraju ◽  
Tomi Akinyemiju ◽  
Neil A. Zakai

Abstract Introduction: Unexplained peripheral blood cytopenia remains a challenge in clinical practice which requires sorting through an array of etiologies from transient abnormalities to premalignant conditions. Clonal hematopoiesis has established an association between cytopenia and hematologic cancer, likely caused by inflammatory responses leading to hematopoietic stress. Similar mechanisms may occur in other organ systems and lead to neoplasia as the link between inflammation and solid tumors is well known. Thus, cytopenia may represent an early marker of serious conditions, including malignancy. Using the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study, we studied the association between cytopenia and cancer mortality. Methods: REGARDS prospectively enrolled 30,239 US black and white adults from 2003 to 2007 (41% black). Sociodemographic and medical data were obtained by phone interview, physical exam, and laboratory studies at enrollment (baseline CBC drawn after 8,000 people were recruited). Cancer death was identified via semiannual phone follow-up through 2018 to ascertain health events and linkage with Social Security Death and National Death Indexes. Cytopenia was defined as presence of 2 or more of the following: 1) hemoglobin below age, sex, and race-specific lowest 5th percentile, 2) white cell count below race-specific lowest 5th percentile, 3) platelet count below lowest 5th percentile, and 4) macrocytosis (MCV &gt;98fL). Participants with baseline cancer, missing CBC, or lost to follow-up were excluded. Cox proportional hazards models were used to calculate hazard of cancer mortality associated with cytopenia, adjusting for demographics (Model 1), Model 1 + risk factors for cancer/anemia (Model 2), and Model 1 + socioeconomics (Model 3). Differences in the association of cytopenia and cancer death by race was tested by cross-product interaction terms and Inverse Odds Ratio Weighting (IORW) mediation analysis was conducted to study the effect of cytopenia as mediator in the race-cancer death interaction. Results: The analysis population included 19,028 participants, 62% were female and 60% were white. Median follow up was 9 years. There were 1112 (5.8%) cancer deaths and 3725 (19.6%) deaths from other causes. Cytopenia was present in 383 (2%) participants, of which 250 (65%) were white and 113 (35%) were black. Cytopenia prevalence increased by age and was higher in males (56%). Cytopenia was associated with increased risk of cancer mortality in all multivariate models adjusting for demographics (HR=1.60, 95%CI 1.16-2.21), cancer risk factors (HR=1.67, 95%CI 1.2-2.32), and socioeconomics (HR=1.58, 95%CI 1.12-2.23). Anemia and macrocytosis, but not leukopenia and thrombocytopenia, were hematologic parameters individually associated with risk of cancer death (Table 1). The 10-year cumulative incidence of cancer death was 13% for participants with baseline cytopenia vs. 6.5% for those without cytopenia (p&lt;0.01, Figure 1). The race by cytopenia interaction term was significant with higher HR for cancer mortality in blacks compared to whites in all models: 2.01 vs 1.41, p=0.016 in model 1 (demographics), 2.12 vs 1.45, p=0.009 in model 2 (cancer risk factors), 1.82 vs 1.44, p=0.04 in model 3 (socioeconomics). Anemia and macrocytosis were individual hematologic parameters with higher HR for cancer death in blacks compared to whites and significant race by cytopenia interaction terms across all models (Table 2). Mediation analysis by IORW method showed that cytopenia was not a significant mediator in the pathway between the race and cancer death association (not shown). Discussion: In a large biracial prospective cohort, cytopenia was associated with increased risk of cancer mortality after adjusting for demographics, socioeconomics, and cancer risk factors. Cytopenia was a race-specific risk factor for cancer death affecting blacks more than whites, but not a mediator of the race and cancer death association. We conclude that 1) cytopenia is a risk factor for cancer death, with stronger association in blacks than whites, and 2) race is an effect modifier for the association of cytopenia with cancer death, but cytopenia is not a mediator of the black to white difference in cancer mortality. These results can inform further studies aimed at clarifying racial disparities in cancer death through theorized mechanisms such as clonal hematopoiesis. Figure 1 Figure 1. Disclosures Gangaraju: Alexion: Consultancy; Sanofi Genzyme: Consultancy.


2020 ◽  
Vol 189 (9) ◽  
pp. 942-950
Author(s):  
Yejin Mok ◽  
Shoshana H Ballew ◽  
Yingying Sang ◽  
Josef Coresh ◽  
Corinne E Joshu ◽  
...  

Abstract Few studies have comprehensively investigated the association of 2 key kidney disease measures, estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR), with cancer incidence. In 8,935 participants at the baseline (1996–1998) from the Atherosclerosis Risk in Communities study, we quantified the associations of eGFR (based on creatinine and cystatin C) and ACR with cancer risk using Cox regression models adjusted for potential confounders. Due to changing guidelines for prostate cancer screening during the follow-up period, we investigated overall cancer, overall nonprostate cancer, and site-specific cancer. During a median follow-up of 14.7 years, 2,030 incident cancer cases occurred. In demographically adjusted models, low eGFR and high ACR were associated with cancer incidence (both overall and overall nonprostate cancer). These associations were attenuated after adjusting for other shared risk factors, with a significant association remaining only for ACR (≥103 compared with 5 mg/g) and overall nonprostate cancer. For site-specific cancer, only high ACR showed a significant association with lung and urinary tract cancers. Of these, the association between ACR and lung cancer appeared most robust in several sensitivity analyses. Kidney disease measures, particularly high ACR, were independently associated with cancer risk. The association between ACR and lung cancer was uniquely robust, warranting future studies to explore potential mechanisms.


SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A382-A382
Author(s):  
A Sillah ◽  
M Biggs ◽  
J Nieto ◽  
N Watson ◽  
D Gozal ◽  
...  

Abstract Introduction Even in the absence of a formal diagnosis, sleep problems (SP) are frequently indicative of an underlying sleep disorder, such as obstructive sleep apnea, which may be adversely associated with cancer risk and cancer outcomes. Methods We assessed the association of self-reported SP with incident cancer (N=4,997, excluding prevalent cancers) and cancer mortality (N=5849) among the participants of Cardiovascular Health Study (CHS), a population-based study of adults aged &gt;=65 years recruited from 4 US communities. Participants reported SP (daytime sleepiness, observed apnea and snoring) yearly from 1989-1994; these self-reported symptoms have been validated against objective sleep measures assessed within a subset of CHS participants (n= 1240) who received a home polysomnography as part of the Sleep Heart Health Study. Cancer incidence was ascertained through linkage with state cancer registries through 2005; cancer specific death was adjudicated through 2015. We used Cox proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (CI) for associations of baseline SP with subsequent cancer incidence and cancer mortality, adjusting for baseline sociodemographics, lifestyle factors, and medical history. Results The mean age (SD) of the study population was 73 (6) years, 56% were female, and 84% were white. The prevalence of SP was 17% for daytime sleepiness, 8% for observed apnea, and 24% for snoring; 63% reported none of the 3 SP. Overall, 1,130 first incident cancers and 1,014 cancer deaths were identified over median follow-up of 12 and 13 years, respectively. Compared to participants who reported no SP, the risk of incident cancer was inversely associated with daytime sleepiness (HR 0.86 [95% CI 0.70-1.04]), observed apnea (HR 0.74 [0.56-1.00]), and snoring (HR 0.80 [0.68-0.95]). Cancer mortality HR (95% CI) estimates were 1.00 (0.82-1.21) for daytime sleepiness, 0.77 (0.57-1.04) for observed apnea, and 0.88 (0.74, 1.04) for snoring. Conclusion Symptoms indicating SP reported at baseline were not associated with increased cancer incidence or cancer mortality. Ongoing analyses are focused on the impact of longitudinal SP (time dependent, cumulative average) to ensure an adequate latency period is incorporated into our analysis of the association between SP and cancer risk and mortality. Support NIHT32CA09488017


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 1002-1002 ◽  
Author(s):  
A. Bardia ◽  
A. H. Wang ◽  
L. C. Hartmann ◽  
J. E. Olson ◽  
C. M. Vachon ◽  
...  

1002 Background: Physical activity is a modifiable breast cancer risk factor, perhaps mediating risk reduction through regulation of estrogen metabolism. Evidence regarding effect of physical activity is conflicting partly because breast cancer is a heterogenous constellation of different tumor subtypes with differing etiologies. No prospective study has examined the relationship between physical activity and breast cancer incidence based on ER/PR status or histological subtype. Objective: Examine effect of physical activity on breast cancer incidence based on ER/PR status and histological subtypes of breast cancer. Methods: The Iowa Women’s Health Study is a prospective cohort study of postmenopausal women (N=41,837). Physical activity was self-reported on baseline questionnaire, and three levels (high, medium and low) were defined. Breast cancer incidence, histologic subtype and ER/PR status, through 18 years of follow-up, were ascertained by linkage with the Iowa SEER Cancer Registry. Cox proportional hazards models were used to estimate multivariate relative risks (RRs) and 95% confidence intervals (CIs) of breast cancer, adjusting for other breast cancer risk factors. Results: During 554,819 person-years of follow-up, 2548 incident cases of breast cancer were observed. High physical activity was associated with decreased risk for breast cancer (RR 0.91, 95 % CI 0.81–1.01) compared to low activity. The protective effect was most marked in ER+/PR− (RR 0.66, CI 0.46–0.94), intermediate in ER−/PR− (RR 0.80, CI 0.56–1.15), weakest in ER+/PR+ (RR 0.94, CI 0.81–1.08), and elevated in ER-/PR+ (RR 1.42, CI 0.67–3.01) tumors. Higher physical activity was also associated with a decreased risk of invasive ductal/lobular carcinoma (RR 0.90, CI 0.80–1.02), but not with invasive breast cancer with a favorable histology (RR 1.19, CI 0.78–1.81). Conclusions: Higher physical activity was associated with a 10% decreased risk of breast cancer. Unexpectedly, risk reduction was most marked in PR- tumors, particularly ER+/PR-, and the more aggressive histologic forms. Further studies are needed to confirm these findings, and also evaluate other risk factors based on ER/PR status and histological subtypes. No significant financial relationships to disclose.


2017 ◽  
Vol 35 (28) ◽  
pp. 3230-3239 ◽  
Author(s):  
Agnès Fournier ◽  
Sylvie Mesrine ◽  
Amandine Gelot ◽  
Guy Fagherazzi ◽  
Laura Baglietto ◽  
...  

Purpose To assess whether bisphosphonate (BP) use is associated with decreased breast cancer incidence in a cohort of postmenopausal women. Methods The study population included 64,438 postmenopausal women participating in the French E3N (Etude Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale) prospective cohort, with data self-reported in biennial questionnaires matched with data from a drug reimbursement database. Exposure to BPs and the use of other osteoporosis treatments during follow-up were determined using reimbursement data. Other covariates (breast cancer risk factors, clinical risk factors for osteoporotic fractures, and bone mineral density surveillance) originated from the questionnaires. Hazard ratios (HRs) of breast cancer were estimated using Cox proportional hazards models, considering exposure as a time-varying variable. Results Over an average of 7.2 years of follow-up (2004 to 2011), 2,407 first primary breast cancer cases were identified. The HR of breast cancer associated with exposure to BPs was 0.98 (95% CI, 0.85 to 1.12). We found no effect modification by age, body mass index, time since menopause, use of hormone replacement therapy, use of calcium supplements, or use of vitamin D supplements. There was no heterogeneity across BP molecules and no trend according to cumulative dose, duration of use, or time since last use. We observed a decrease in breast cancer risk restricted to the year after treatment initiation (HR, 0.56; 95% CI, 0.36 to 0.87), which was likely explained by healthy screenee bias. Finally, we did not find any variation in HRs across breast carcinomas defined by their estrogen receptor or invasive or in situ status. Conclusion In our observational cohort of postmenopausal women observed from 2004 to 2011, BP use, likely prescribed for the management of osteoporosis, was not associated with decreased breast cancer incidence.


2019 ◽  
Author(s):  
Leif Aage Strand ◽  
Jan Ivar Martinsen ◽  
Einar Kristian Borud

Abstract Introduction In 2012, Norwegian news media reported on cases of brain cancer among Norwegian peacekeeping troops who served in Kosovo, allegedly caused by exposure to depleted uranium fired during airstrikes before the peacekeepers arrived in 1999. A first study followed 6076 military men and women with peacekeeping service in Kosovo during 1999–2011 for cancers and deaths throughout 2011. The study did not support to the idea that peacekeeping service in Kosovo could lead to increased risk of brain cancer or other cancers. However, the average time of follow-up (10.6 years) was rather short for cancer development; therefore the aim of the present study was to evaluate cancer risk and general mortality in an updated cohort after 5 years of additional follow-up. Materials and Methods The updated cohort consisted of 6,159 peacekeepers (5,884 men and 275 women) who served in Kosovo during 1999–2016 and were followed for cancer incidence and mortality from all causes combined throughout 2016. We calculated standardized incidence ratios (SIR) for cancer and standardized mortality ratios (SMR) from national population rates. Poisson regression was used to assess the effect of length of service (<1 year vs. ≥1 year) on cancer risk. Results We observed 149 cancer cases and 75 deaths in the updated cohort. Observed cancer incidence did not exceed national rates. In men, the SIR for brain cancer was 0.73 (95% confidence interval (CI) 0.32–1.44), based on eight cases, while the risk of colon cancer was lowered (SIR = 0.14, 95% CI 0.00–0.79). The Poisson regression showed no effect of service duration on all-site cancer incidence. Mortality from all causes combined was lower than expected (SMR = 0.62, 95% CI 0.49–0.78) and in accordance with a “healthy soldier effect”. Conclusion The extended follow-up did not give support to the suggestion that peacekeeping service in Kosovo could lead to increased risk of cancer.


BMJ ◽  
2019 ◽  
pp. l5383 ◽  
Author(s):  
Maaike Buskermolen ◽  
Dayna R Cenin ◽  
Lise M Helsingen ◽  
Gordon Guyatt ◽  
Per Olav Vandvik ◽  
...  

Abstract Objective To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. Design Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). Setting A parallel guideline committee ( BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. Population Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). Comparisons Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. Main outcome measures Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. Results Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. Conclusions Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies.


Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2560
Author(s):  
Injeong Ryu ◽  
Minji Kwon ◽  
Cheongmin Sohn ◽  
Nitin Shivappa ◽  
James R. Hébert ◽  
...  

Several epidemiological studies have shown that there are consistent positive associations between dietary inflammatory index (DII®) and cancer incidence in Western populations. However, few DII-cancer studies have been conducted in East Asian populations. In a large cohort representative of the general Korean population, we investigated whether the DII is associated with overall cancer risk. A total of 163,660 participants (56,781 males and 106,879 females) had evaluable data for analyses. This follow-up study was carried out over the course of 7.9 years. DII was calculated based on Semi-Quantitative Food-Frequency Questionnaire (SQ-FFQ) data for 106 food items. Cancers were self-reported based on notification by the participants’ medical doctors. Multivariable Cox proportional hazard regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). After the follow-up, 1,643 cases of cancer (520 males and 1123 females) had developed. In a fully adjusted model, women in the highest DII quintile showed a 44% increased risk of getting cancer (HRQ5vsQ1 = 1.44; 95% CI = 1.14–1.82; p-trend = 0.0006), while men showed no apparent association (HRQ5vsQ1 = 0.80; 95% CI = 0.58–1.10). These results indicate that in Korean women, a more pro-inflammatory diet is associated with a higher risk of cancer incidence.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
C.C Van 't Klooster ◽  
P.M Ridker ◽  
N.R Cook ◽  
J.G.J.V Aerts ◽  
J Westerink ◽  
...  

Abstract Background As treatment for cardiovascular disease (CVD) has improved substantially over the last decades, more patients survive acute CVD manifestations and are at risk for developing cancer as well as recurrent CVD. Due to similar risk factors, including smoking and obesity, patients with established CVD are at higher risk for cancer. Objectives The aim of this study was to develop and externally validate prediction models for the estimation of 10-year and lifetime risk for total, colorectal, and lung cancer in patients with established CVD. Methods Data from patients with established CVD from the UCC-SMART prospective cohort study (N=7,280) were used for model development, and data from the CANTOS trial (N=9,322) were used for model validation. Predictors were selected based on previously published cancer risk prediction models or cancer risk factors, easy clinical availability, and availability in the derivation dataset (UCC-SMART cohort). A Fine and Gray competing risk-adjusted lifetime model was developed for total, colorectal, and lung cancer. Results Selected predictors were age, sex, smoking status, weight, height, alcohol use, antiplatelet use, diabetes mellitus, and C-reactive protein. External calibration for 4-year risks of the total cancer, colorectal cancer, and lung cancer models was good (Figure 1), and C-statistics were 0.63–0.74 in the CANTOS trial population. Median predicted lifetime risks in CANTOS were 26% (range 1%-52%) for total cancer, 4% (range 0%-13%) for colorectal cancer, and 5% (range 0%-37%) for lung cancer. Conclusions Lifetime and 10-year risk of cancer can be estimated with easy to measure variables in patients with established CVD, showing a wide distribution of predicted lifetime risks for total cancer and lung cancer. Using these lifetime models in clinical practice could increase understanding of cancer risk and aid in emphasizing healthy lifestyle changes. Figure 1. Calibration plots of cancer models Funding Acknowledgement Type of funding source: Public hospital(s). Main funding source(s): University Medical Center; Additional funding: CANTOS trial was funded by Novartis Pharmaceuticals.


Sign in / Sign up

Export Citation Format

Share Document